Clinical Trials
15
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
- Conditions
- Erythema Nodosum Leprosum
- Interventions
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 45
- Registration Number
- NCT07172659
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Harborview Medical Center, University of Washington, Seattle, Washington, United States
🇧🇯Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli, Abomey-Calavi, Benin
Better Options for Lymphatic Filariasis Treatment
- Conditions
- Lymphatic FilariasisScabiesStrongyloidiasis
- Interventions
- Drug: MoxDA - Moxidectin + Diethylcarbamzine (DEC) + AlbendazoleDrug: IDA - Ivermectin + DEC + albendazole
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 5100
- Registration Number
- NCT07159373
- Locations
- 🇫🇯
Ministry of Health and Medical Services Fiji, Suva, Fiji
Efficacy and Safety Study of Moxidectin in Adults With Scabies
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 200
- Registration Number
- NCT05875441
- Locations
- 🇺🇸
LA Universal Research Center, Inc, Los Angeles, California, United States
🇺🇸Evolution Clinical Trials, Miami, Florida, United States
🇺🇸Medical Research of Westchester, Inc, Miami, Florida, United States
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
- Conditions
- Onchocerciasis
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 12997
- Registration Number
- NCT04311671
- Locations
- 🇨🇩
Centre de Recherche pour les Maladies Tropicales Negligees, Rethy, Ituri, Congo, The Democratic Republic of the
🇨🇮Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire, Abidjan, Côte D'Ivoire
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Medicines Development for Global Health
- Target Recruit Count
- 36
- Registration Number
- NCT03962062
- Locations
- 🇬🇭
University of Health and Allied Services School of Public Health, Hohoe, Volta Region, Ghana
- Prev
- 1
- 2
- 3
- Next
News
Ghana Approves Moxidectin as First River Blindness-Endemic Country
Ghana's FDA has approved moxidectin 2mg oral tablets for treating river blindness in adults and children aged 4 and older, marking a significant step in disease elimination.